News

David J. Calkins, PhD, is being recognized for his groundbreaking contributions to the field of vision research.

The multi-center, international clinical study is designed to assess the safety and efficacy of novel investigational low-dose atropine eye drops in children 3-17 years old with myopia.

Product is forging a future in ocular regenerative procedures

Researchers at the University of Bonn are evaluating a new imaging technique for the diagnosis of posterior uveitis.

The debate continues about the protective effect of eyeglasses against contracting the COVID-19 virus. Researchers from Denmark reported that their results were inconclusive regarding whether wearing eyeglasses is linked with a decreased risk of COVID-19 infections.

The company has filed an ophthalmic IND submission for the first treatment of ocular conditions associated with DNA damage.

AB 2236, which would reduce the medical education, clinical, and surgical training requirements to become licensed in California to perform eye surgery. Trade organizations and other groups are stepping up to oppose the measure.

Edward J. Holland, MD, discusses how postoperative dry eye disease after refractive and cataract procedures may lead to patient dissatisfaction.

Reducing incidents can reduces cases of infection, transmission among physicians, clinicians.

When paired with SD-OCT, the device also can be used to evaluate photoreceptors.

This award totals $65,000 to support strategic planning implementation.

The IOL has a hybrid design that combines the benefits of central extended depth-of-focus technology and multifocal technology that provides a continuous range of high-quality vision ranging from distance and intermediate and near vision to about 12 to 14 inches.

Researchers in Trinity’s School of Genetics and Microbiology developed a new gene therapy, ophNdi1, that is the first of its kind to directly target mitochondrial function in cells that are malfunctioning in AMD.

Gene therapy has partly restored the function of the retina’s cone receptors in two children who were born completely colorblind, reports a new study led by UCL researchers.

Stoke Therapeutics announced enrollment of the first patient in a prospective natural history study of people ages 8 to 60 who are living with autosomal dominant optic atrophy.

Sight Sciences Inc. is taking the wraps off Sion, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.

According to investigators, the progression of myopia in children may be slowed by a metabolite of caffeine, known as 7-MX.

Alcon and Aerie Pharmaceuticals Inc. have announced the companies have entered into a definitive merger agreement through which Alcon will acquire Aerie.

George Waring IV, MD, FACS, points out that supplementation and customized procedures are in the offing.

A test to detect and quantify TDP-43 deposits in the retina provides this capability for the first time and can be performed using commercially available and widely utilized diagnostic cameras.

According to researchers, functional assessments and education are critical to an early diagnosis.

In embryonic stages, tactile stimuli simultaneously activate tactile and visual neural pathways. Shortly after birth, both pathways reorganize to allow separate processing of touch and vision. The change of pathway is facilitated by the activity waves of the retina, which act as railroads that direct the stimuli of each sensory modality to the corresponding cortex, so that we can perceive them separately.

Reservoir restoration can re establish the normal anatomy and function of the conjunctiva.

By creating customized packages that incorporate the range of diagnostic and treatment options available, practices can simplify dry eye management and improve patients' outcomes.

APOE4 gene associated with Alzheimer’s disease risk was found to protect mice from glaucoma. Research team also prevented retinal ganglion cell death by blocking the APOE signaling pathway, pointing to a potential treatment strategy for glaucoma.

Oyster Point Pharma Inc. today announced that the largest Medicare pharmacy benefit manager in the United States will add its varenicline solution nasal spray (Tyrvaya) for the treatment of dry eye on its Medicare Part D formularies, effective September 1.

A team of investigators has found that myopic refractive error is linked with an increased risk of primary open-angle glaucoma, and they indicate that the connection has a genetic foundation.

According to Johns Hopkins Medicine researchers, as little as $65 per year appears to influence practitioners, making them up to twice as likely to prescribe the companies’ brand name eyedrops for glaucoma instead of cheaper generic versions.